Results from clinical II and III trials demonstrated that the adjunctive treatment with A2AR antagonists improves the mobility of PD patients as well as reduces adverse effects of long-term L-DOPA treatment [32,33]. The gene discussed is ADORA2A; the disease is Parkinson disease.